General principles of pharmaceutical solid polymorphism: a supramolecular perspective.
about
Polymorph Impact on the Bioavailability and Stability of Poorly Soluble DrugsInvestigating the latent polymorphism of maleic acidDiffuse scattering and partial disorder in complex structures.Impact of crystal polymorphism on the systemic bioavailability of rifaximin, an antibiotic acting locally in the gastrointestinal tract, in healthy volunteers.A triclinic polymorph of 3-nitro-anilinium chlorideModification of the solid-state nature of sulfathiazole and sulfathiazole sodium by spray dryingComplex Behavior of Caffeine Crystallites on Muscovite Mica SurfacesEffects of humidity and surfaces on the melt crystallization of ibuprofenNew form discovery for the analgesics flurbiprofen and sulindac facilitated by polymer-induced heteronucleation.Influence of Coformer Stoichiometric Ratio on Pharmaceutical Cocrystal Dissolution: Three Cocrystals of Carbamazepine/4-Aminobenzoic Acid.Pharmaceutical Cocrystals and Their Physicochemical Properties.Analysis of solid-state transformations of pharmaceutical compounds using vibrational spectroscopy.Solvent-free dynamic nuclear polarization of amorphous and crystalline ortho-terphenyl.Interactions between drugs and polymers influencing hot melt extrusion.An overview of famotidine polymorphs: solid-state characteristics, thermodynamics, polymorphic transformation and quality control.Recrystallization of commercial carbamazepine samples-a strategy to control dissolution variability.Solid-State Characterization and Interconversion of Recrystallized Amodiaquine Dihydrochloride in Aliphatic Monohydric Alcohols.Preferential Nucleation during Polymorphic Transformations.Liquid anti-solvent recrystallization to enhance dissolution of CRS 74, a new antiretroviral drug.Solvated crystalline forms of nevirapine: thermoanalytical and spectroscopic studies.Pharmaceutical Cocrystal of Piroxicam: Design, Formulation and Evaluation.Surface Mediated Structures: Stabilization of Metastable Polymorphs on the Example of Paracetamol.Enthalpy relaxation studies of two structurally related amorphous drugs and their binary dispersions.A comparative study of methods to compute the free energy of an ordered assembly by molecular simulation.The relative stability of xylazine hydrochloride polymorphous forms.Characterization of multicomponent crystal formed between indomethacin and lidocaine.Anomalous thermal expansion of an organic crystal--implications for elucidating the mechanism of an enantiotropic phase transformation.On the hydrates of codeine phosphate: the remarkable influence of hydrogen bonding on the crystal size.Solid-State Form Characterization of Riparin I.Vibrational spectroscopic investigation of polymorphs and cocrystals of indomethacin.Polymorphism of griseofulvin: concomitant crystallization from the melt and a single crystal structure of a metastable polymorph with anomalously large thermal expansion.Solid-state form screen of cardiosulfa and its analogues.On the glass temperature under extreme pressures.Influence of Codium tomentosum Extract in the Properties of Alginate and Chitosan Edible Films.Polymorphism in α-sexithiophene crystals: relative stability and transition path.Survey and analysis of crystal polymorphism in organic structures.Characterization of Crystalline Phase‐Transformations in Theophylline by Time‐Domain Terahertz SpectroscopyDevelopment and Evaluation of a Reconstitutable Dry Suspension to Improve the Dissolution and Oral Absorption of Poorly Water-Soluble CelecoxibConformational polymorphism of the antidiabetic drug chlorpropamideEffects of Polymeric Additives on the Crystallization and Release Behavior of Amorphous Ibuprofen
P2860
Q26779030-AD3C12E8-7E28-48C8-8DE0-5898CACEF36DQ28286724-414DCD23-B873-410A-8AE9-DF77EE7487D7Q34473238-E5F923D9-7A7D-4E50-84F9-842A06F00A80Q34757166-D8A9D21D-DA80-4038-A51E-B3A520B521B6Q35542531-93B59936-498B-4E34-99F4-01DD623351E9Q35999134-C6B687BB-EF4C-4E72-BFB0-D5D3910D822FQ36032206-0137C4B4-D334-4D9D-9BE0-3E3C8AD7741CQ36202469-06937FBD-5794-47C0-B600-1EB746D3E37FQ36969025-27958DC4-C64C-4889-9C5E-E4E190BBCF2EQ37155004-497D3B22-69F9-4510-8E53-82AE9156BB68Q37510600-254CDE8F-C6AB-4B75-8BAC-B2DC41BCD723Q37585656-B6CAD5EE-6BA9-43C3-B4DF-273831EE33B9Q37605362-7D95F996-92ED-4B7D-9F1B-7BA83982DC26Q38170190-5E4D6889-E868-4C7D-ADB2-6D614F28CFAAQ38191851-54294759-0D19-4300-AE32-55C0023F7E55Q41833144-F71B993F-5C44-481F-BA17-252A36766B13Q41987417-C33E966C-5970-4E5A-A8D2-98FAA57D3CBBQ42016785-A5253B26-9FAF-473D-9915-2923DF5C4FBBQ42153618-79570788-3BB3-42D2-879B-ED0E8240C2A5Q42380491-4F26FF9C-E2D0-4991-9DB7-382431C9BB62Q42658216-CE21E20A-F82F-4A3F-A03F-9A646A0082D3Q42776268-6A500CF3-DB34-47D4-93A6-C21A266D68EAQ42918134-6F771F7E-6D91-4FEB-8A69-6634CC08CE21Q44078779-A58F5B27-7C94-4792-8AC5-C1544977990EQ45916811-E4246AC8-6712-4ED0-BB43-D656B12EA70FQ45998050-716A8825-38B3-4FB9-9080-AE6D25C894A3Q46771399-4EC7104B-3F7E-4E9A-B905-43BF2BE77440Q47178195-408B60B5-5889-4AD8-8813-679516459F29Q47908355-2AACB925-E86B-4067-95B6-7405BAB8D3F3Q47938746-679140AB-88E4-44E2-ABB4-057447E12306Q49875406-EC0D3472-3743-4E69-971D-CC4F1967A97CQ51042793-B3CD783A-6836-46D5-A479-0B9D9740F2CFQ51915783-D3738F1E-8A5D-4EA5-A81F-868850D8788BQ52609659-C994241D-845E-4921-9190-D7550A808B73Q52852271-49DA8D98-4B10-4B32-B751-238DDB464314Q54943838-07502990-9E43-484B-9249-74DC0A544EBCQ56829163-29D63129-4BB0-4CAE-BC7A-2A27A15F112CQ58692942-E8F38144-AEEC-4636-95DF-B16794A68D8BQ58860604-0FB32359-0EB0-4553-8267-288411091C11Q59018587-93096A21-BDB9-4D22-B62C-156F027391EF
P2860
General principles of pharmaceutical solid polymorphism: a supramolecular perspective.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
General principles of pharmaceutical solid polymorphism: a supramolecular perspective.
@ast
General principles of pharmaceutical solid polymorphism: a supramolecular perspective.
@en
type
label
General principles of pharmaceutical solid polymorphism: a supramolecular perspective.
@ast
General principles of pharmaceutical solid polymorphism: a supramolecular perspective.
@en
prefLabel
General principles of pharmaceutical solid polymorphism: a supramolecular perspective.
@ast
General principles of pharmaceutical solid polymorphism: a supramolecular perspective.
@en
P2093
P1476
General principles of pharmaceutical solid polymorphism: a supramolecular perspective.
@en
P2093
Adam J Matzger
Adivaraha Jayasankar
Barbara Rodríguez-Spong
Christopher P Price
Naír Rodríguez-Hornedo
P304
P356
10.1016/J.ADDR.2003.10.005
P407
P577
2004-02-01T00:00:00Z